🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New review: The transcription factor TCF-1 has multiple roles during T cell development and in mature T cells. Gounari and Khazaie review the potential mechanisms by which TCF-1 regulates gene expression rdcu.be/cNvlc

Photo of the Day: My mentor on the bench👀

Check out the newest work published nature from our lab by Masao Hashimoto showing that the combination of IL2 and PD1 blockade modifies the CD8 T cell exhaustion program. 1/🧵 nature.com/articles/s4158…

In a new Review Andrew Chow @KarloPerica Klebanoff_Lab & Jedd Wolchok discuss the immunobiology and clinical implications of T cell exhaustion for cancer immunotherapy: nature.com/articles/s4157… Memorial Sloan Kettering Cancer Center Weill Cornell Medicine

Great work from Joanina Gicobi, Ph.D. (She/Her) et al on the metabolic features of resilient CD8-T cells. Malic enzyme 1 (ME1) is a critical factor for ROS homeostasis and cytotoxic function #Immunometabolism #cd8tcells

Science Magazine's special issue on #Autoimmunity organized by Gemma Alderton & me is out now! Intro: bit.ly/Sci_adi2318 PS: bit.ly/Sci_adg7489 Rev 1: bit.ly/Sci_adg6425 Rev 2: bit.ly/Sci_adg6427 Rev 3: bit.ly/Sci_adg2992

Such a fun experience for attending #AAI2023 for the first time and present my poster. It is great to learn all the exciting science going on and interact with all the talented researchers!😆The American Association of Immunologists (AAI)

Some new work from our lab: We report a novel founder mutation in an isolated population resulting in IL10RB deficiency. This work was lead by Zhiming Mao, Michael Betti and also included our 2 undergrads, Shamel Basaria and Kathy Liu tinyurl.com/35r9j3zy

CD8+ T cells in the cancer-immunity cycle: CD8+ T cells are “end effectors” of cancer immunity. Wherry, Kaech, Giles, & Globig review the current understanding of CD8+ T cell differentiation and function in cancer, discussing recent advances within a four-signal framework that

Very exciting to work with ⁦Joanina Gicobi, Ph.D. (She/Her)⁩ and ⁦Haidong Dong⁩ on this newly published paper about resilient CD8+ T cells in ⁦Science Advances⁩. So happy to be part of the team! science.org/doi/10.1126/sc…

Our newly approved strategic initiative, Bold. Forward. Unbound. in Rochester, will transform healthcare at Mayo Clinic and beyond. Read more: mayocl.in/46EAQfA #BoldForwardUnbound

Same yet different — how lymph node heterogeneity affects immune responses dlvr.it/T08YN9

Cancer is a disease should be treated at single cell level, to that end, the immune system seems to be able to do it. That is what I can advise my graduate students at the beginning of 2024.

New immune cell engagers for cancer immunotherapy dlvr.it/T1tKWV

What is key PD-1 signaling regulation to improve cytotoxic and memory T cell function? Ask Zhiming Mao at poster today eppro01.ativ.me/appinfo.php?pa… #AACR24 Haidong Dong Mayo Clinic Comprehensive Cancer Center

AI and immunology Immunity cell.com/immunity/fullt…

PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity biorxiv.org/content/10.110… Haidong Dong Zhiming Mao

A key feature of resilient T cells is revealed: Lysosomal NKG7 restrains mTORC1 activity to promote CD8+ T cell durability and tumor control. rdcu.be/d9RXx Congratulations!!! June, Dan, Henrique and all authors!!